Contents

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration (TREND)

Jan, 2018

Clinical Trial

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.

Silva R, Berta A, Larsen M, Macfadden W, Feller C, Monés J; TREND Study Group.

Ophthalmology. 2018 Jan;125(1):57-65.
Full text | Metrics.

Main finding: Ranibizumab 0.5 mg administered according to a treat-and-extend was statistically noninferior and clinically comparable with a monthly regimen in improving visual acuity from baseline to the end of study

 

  • Purpose: To evaluate the efficacy and safety of ranibizumab 0.5 mg treat-and-extend versus monthly regimens in patients with CNV secondary to AMD
  • Study type: Randomized controlled Trial
  • Condition: Neovascular AMD

Participants: treatment-naïve active subfoveal CNV secondary to AMD

 

  • n=650

 

Intervention:

 

Group 1: Ranibizumab 0.5mg treat-and-extend regimen
Group 2: Ranibizumab 0.5mg monthly regimen

The T&E regimen was noninferior to the monthly regimen, with mean BCVA change from baseline of 6.2 versus 8.1 letters respectively.

 

Fewer injections were required in patients receiving the T&E (8.7) versus monthly (11.1) regimen.

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed